Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
At UCB, we take our responsibility to the planet very seriously, working in the following 7 key areas #UCB90 #GreenStrategy: ???? Regulatory compliance ???? Natural resources ???? Energy efficiency ???? Green chemistry ???? Air emissions ???? Waste stream
— UCB News (@ucb_news) 12.10.2018 -
UCB is committed to the goals of the rheumatology community on #WorldArthritisDay – and every day https://t.co/4CySKP8oFc @ArthritisDay #ConnectToday https://t.co/PghObOXz3Q
— UCB News (@ucb_news) 12.10.2018 -
UCB is pleased to join the Partner Program of the International Federation of Psoriasis Associations https://t.co/CgqWFwW2ju https://t.co/EgKzIEC0tS
— UCB News (@ucb_news) 10.10.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
